The European Medical Journal shared this video of Hilary Glen, PhD, talking about the clinical impact of emerging treatments like “abiraterone acetate and enzalutamide in post-chemotherapy and pre-chemotherapy settings, in patients with metastatic castration-resistant prostate cancer.”
Prostate Cancer: Quality of Life and New Therapeutic Options for Metastatic Castration-Resistant Prostate Cancer
